成人弥漫性胶质瘤分子分型:IDH1/IDH2、ATRX与1p/19q结果冲突
2016年WHO中枢神经系统肿瘤分类将IDH1/IDH2突变和1p/19q共缺失纳入弥漫性胶质瘤诊断,使分子检测成为常规。本文报告6例因分子检测结果冲突而诊断困难的弥漫性胶质瘤,提示将新分类标准引入日常实践可能出现的并发症,旨在提醒病理界注意潜在误诊风险。
要点
- 新WHO分类要求IDH突变和1p/19q共缺失同时存在才诊断少突胶质细胞瘤。
- 分子检测结果冲突时诊断困难,需警惕潜在误诊。
- 本文报告6例分子结果冲突的弥漫性胶质瘤病例。
核心结论
- 将2016年WHO中枢神经系统肿瘤分类标准引入常规实践时,分子检测结果冲突可造成诊断挑战和潜在误诊风险。
研究设计与样本
- 本文为病例系列,报告6例因分子检测结果冲突而诊断困难的弥漫性胶质瘤病例。
主要发现
- 6例弥漫性胶质瘤因分子检测结果冲突而呈现诊断挑战。
- 这些病例体现了引入2016年WHO中枢神经系统肿瘤分类诊断标准后可能出现的并发症。
关键数值与推荐
- 新分类下「少突胶质细胞瘤,IDH突变且1p/19q共缺失」要求同时存在IDH1或IDH2突变和1p/19q共缺失。
临床怎么用
- 病理医生在日常诊断中应关注分子检测结果冲突,以降低潜在误诊风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Until recently, the diagnosis of brain tumors was primarily based on microscopic examination of hematoxylin and eosin-stained tissue sections. The updated World Health Organization (WHO) Classification of Tumours of the Central Nervous System incorporates genetic alterations into the classification system, with the goal of creating more homogenous disease categories with greater prognostic value. Hence, under the new classification system, the diagnosis of diffuse gliomas incorporates the evaluation of mutations in the IDH1 and IDH2 genes and simultaneous deletion of chromosomes 1p and 19q. For example, although under the 2007 WHO classification system, oligodendrogliomas could be diagnosed based solely on the presence of characteristic histologic features, the newly molecularly defined entity of "oligodendroglioma, IDH-mutant and 1p/19q codeleted" requires the presence of both an IDH1 or IDH2 mutation and 1p/19q codeletion. Given that diagnosis requires evaluation of critical genetic alterations, molecular diagnostics is becoming an increasingly important aspect of clinical oncologic neuropathology practice. As molecular testing is applied more frequently to the diagnosis of brain tumors, inconsistent or conflicting molecular information will create diagnostic challenges. Here we present 6 cases of diffuse glioma that presented a diagnostic challenge due to conflicting molecular testing results. These cases exemplify some of the potential complications that arise when introducing the new 2016 central nervous system WHO classification system diagnostic criteria into routine clinical practice. We aim to alert the general practice pathology community to these potential conflicts to help mitigate the risk of potential misdiagnosis.
引用
- Ballester LY, Huse JT, Tang G, et al. Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results. Hum Pathol. 2017. PMID: 28549927. doi:10.1016/j.humpath.2017.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。